A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Abstract

Background: This phase II trial (Cancer and Leukemia Group B 90102) sought to determine the efficacy of cisplatin, standard infusion of gemcitabine and gefitinib in patients with advanced urothelial carcinoma.Patients and methods: Eligible patients had previously untreated measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status of zero to two and creatinine clearance >50 ml/min. Treatment consisted of cisplatin 70 mg/m 2 day 1 and gemcitabine 1000 mg/m 2 on days 1 and 8 given every 3 weeks concurrent with gefitinib 500 mg/day orally for six cycles. Maintenance gefitinib 500 mg/day was continued for responding or stable disease.Results: Fifty-four of 58 patients were assessable. Twelve patients (22%) had node-only disease, and 25 (46%) had an ECOG performance status of zero. There were 23 objective responses for an overall response rate of 42.6% [95% confidence interval (CI) 29.2% to 56.8%]. The median survival time was 15.1 months (95% CI 11.1-21.7 months) and the median time to progression was 7.4 months (95% CI 5.6-9.2 months). Conclusions:The combination of cisplatin, gemcitabine and gefitinib is well tolerated and active in advanced transitional cell carcinoma. The addition of gefitinib does not appear to improve response rate or survival in comparison to historical controls of cisplatin and gemcitabine alone.

A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

“…The ORR and median TTP in this trial were similar to those observed in other studies of GC and MVAC chemotherapy. 52 A phase 2 trial that evaluated trastuzumab in combination with paclitaxel, carboplatin, and gemcitabine was conducted in 109 patients with advanced HER-2 overexpressing TCC (defined by IHC or fluorescence in situ hybridization). The ORR was 70%, with 5 patients achieving a CR.…”

New Directions for Biologic Targets in Urothelial Carcinoma

“…Again, however, preclinical activity has not translated into clinically relevant activity. A phase II study of GC plus the TKI gefitinib showed an ORR of 36% and MS of 11.1 months, but there was excessive toxicity (67). A similar study of GC plus the monoclonal antibody cetuximab is also under way.…”

Muscle-invasive urothelial bladder cancer: an update on systemic therapy

“…The monotherapy arm had poor results with most patients progressing at the first evaluation, but the dual therapy arm showed an ORR of 25%, median PFS of 16.4 weeks, and median OS of 42 weeks, suggesting that cetuximab may improve the efficacy of paclitaxel in this patient population. Two earlier phase II studies with gefitinib, an EGFR TKI, in both the first-and second-line setting for patients with advanced UC did not yield any improvements in PFS or OS [Philips et al 2009;Petrylak et al 2010]. [Wulfing et al 2009].…”